MarketCapExport financials
Integer Holdings Corporation (ITGR)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Integer Holdings Corporation ITGR
$ 126.66
0.03%
Facebook
X
Telegram
Integer Holdings Corporation Financial Ratios 2025-2009 | ITGR
Brief overview of Integer Holdings Corporation's valuation multiples
The review covers five available annual periods spanning 2021 to 2025.
Key multiples at the end of the period are P/E 28.96x (median 36.73x), EV/EBITDA 18.19x (median 15.01x), P/S 1.61x (median 2.14x). Valuation is roughly 18% below five-year reference levels. The discount may reflect opportunity or higher perceived risk.
The 1/P/E calculation produces a 3.5% earnings yield. It does not capture future growth or capital structure.
End-period return metrics are ROE 5.9%, ROA 3%, ROCE 12.7%. Profitability remains low. Market valuation has limited fundamental support until resource returns improve.
Price, earnings and growth produce a PEG of 2.56x. A high value reduces the cushion if growth slows.
The cash conversion cycle remains near its former level at 96.8 days after 87 days.
Conclusion
Integer Holdings Corporation's multiples look low against history, but fundamental returns do not yet provide convincing support.
Annual Financial Ratios Integer Holdings Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 29.0 | 38.2 | 36.8 | 36.7 | 28.6 | 37.5 | 29.7 | 15.6 | 24.5 | -134.0 | 22.7 | 29.6 | - | -133.1 | 16.3 | 13.3 | - | |
P/S |
1.6 | 2.7 | 2.1 | 1.8 | 2.3 | 2.7 | 2.3 | 2.2 | 1.4 | 1.3 | 1.8 | 1.6 | - | 1.0 | 0.9 | - | - |
EPS |
3.0 | 3.6 | 2.7 | 2 | 2.9 | 2.4 | 3.0 | 5.2 | 2.1 | 0.2 | 2.2 | 1.5 | 0.5 | -0.2 | 1.4 | 1.4 | - |
EV (Enterprise Value) |
4.62 B | 5.99 B | 4.74 B | 3.79 B | 3.98 B | 3.95 B | 4.05 B | 3.86 B | 3.55 B | 3.1 B | 1.53 B | 1.39 B | - | 1.03 B | 916 M | 769 M | -22.1 M |
EBITDA per Share |
10.1 | 9.5 | 7.87 | 6.18 | 6.58 | 6.09 | 7.47 | 8.54 | 7.13 | 2.19 | 4.35 | 3.85 | - | 3.06 | 4.64 | 4.54 | - |
EV/EBITDA |
13.1 | 18.8 | 18.1 | 18.5 | 18.3 | 19.7 | 15.0 | 12.5 | 13.9 | 45.4 | 12.0 | 12.7 | - | 11.7 | 6.7 | 7.3 | - |
PEG |
2.56 | 6.06 | -111.49 | -19.94 | 0.64 | 1.14 | -0.69 | 0.11 | 0.02 | 1.18 | 0.47 | -0.04 | - | 1.16 | -6.25 | - | - |
P/B |
1.7 | 2.8 | 2.2 | 1.7 | 2.0 | 2.3 | 2.5 | 2.5 | 1.8 | 1.2 | 2.1 | 2.0 | - | 1.3 | 1.2 | 1.0 | - |
P/CF |
15.2 | 22.3 | 18.5 | 20.9 | 17.7 | 16.0 | 24.4 | 21.4 | 16.0 | -31.7 | 22.3 | 28.2 | - | 27.0 | 8.0 | 5.7 | - |
ROE % |
5.89 | 7.40 | 5.97 | 4.68 | 7.15 | 6.08 | 8.36 | 15.84 | 7.46 | -0.89 | 9.04 | 6.70 | - | -1.00 | 7.08 | 7.76 | - |
ROA % |
3.01 | 3.90 | 3.08 | 2.38 | 3.75 | 3.26 | 4.09 | 7.22 | 2.34 | -0.25 | 5.81 | 4.08 | - | -0.54 | 3.76 | 4.26 | - |
ROCE % |
6.96 | 7.30 | 6.00 | 4.38 | 5.60 | 5.44 | 7.63 | 8.75 | 4.76 | 0.47 | 8.94 | 7.67 | - | 3.23 | 7.84 | 9.63 | - |
Current Ratio |
2.0 | 2.1 | 2.1 | 2.0 | 2.1 | 2.2 | 2.3 | 2.5 | 2.5 | 2.7 | 3.2 | 3.1 | - | 2.9 | 2.8 | 2.2 | - |
DSO |
58.2 | 50.7 | 53.4 | 55.7 | 50.6 | 59.2 | 62.9 | 55.7 | 62.6 | 99.9 | 67.2 | 63.8 | - | 68.3 | 66.2 | - | - |
DIO |
67.5 | 69.1 | 69.7 | 67.5 | 63.0 | 73.3 | 67.6 | 81.4 | 82.5 | 162.8 | 103.4 | 97.2 | - | 87.5 | 103.3 | - | - |
DPO |
28.9 | 31.9 | 36.5 | 34.7 | 26.5 | 27.0 | 26.3 | 24.5 | 30.1 | 54.5 | 37.1 | 38.2 | - | 37.2 | 38.2 | 14.2 | - |
Operating Cycle |
125.8 | 119.8 | 123.2 | 123.2 | 113.6 | 132.5 | 130.5 | 137.1 | 145.1 | 262.7 | 170.6 | 161.0 | - | 155.8 | 169.5 | - | - |
Cash Conversion Cycle |
96.8 | 87.9 | 86.7 | 88.5 | 87.0 | 105.5 | 104.2 | 112.6 | 115.0 | 208.3 | 133.4 | 122.8 | - | 118.6 | 131.2 | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Financial Ratios Integer Holdings Corporation
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
0.44 | 0.69 | 0.48 | 1.4 | 1.13 | 1.06 | -0.66 | 0.98 | 1.08 | 0.93 | 0.62 | 0.81 | 0.84 | 0.72 | 0.39 | 0.3500000000000001 | 0.48 | 0.63 | 0.34 | 0.6099999999999999 | 0.67 | 0.89 | 0.65 | 0.47 | 0.92 | 0.01 | 0.95 | 0.34 | 0.94 | 0.87 | 0.66 | 0.59 | -0.26 | 0.72 | 0.41 | 1.73 | 0.63 | 0.31 | 0.1 | 0.26 | 0.37 | -0.03 | -0.41 | -0.85 | - | 0.36 | 0.32 | 0.57 | 0.56 | 0.5 | 0.61 | 0.4 | 0.46 | 0.41 | 0.24 | -0.23 | -0.32 | 0.16 | 0.19 | 0.24 | 0.3 | 0.37 | 0.51 |
EBITDA per Share |
1.29 | 1.48 | 1.4 | 1.59 | 2.07 | 2.15 | 1.9 | 3.23 | 2.13 | 2.03 | 1.55 | 3.83 | 1.85 | 1.64 | 1.42 | 3.65 | 1.25 | 1.36 | 1.03 | 3.56 | 1.31 | 1.51 | 1.37 | 3.15 | 1.52 | 0.59 | 1.66 | 1.58 | 1.72 | 1.81 | 1.51 | 582 | 1.59 | 1.72 | 1.28 | 435 | 1.46 | 1.5 | 1.21 | 1.03 | 1.51 | 1.26 | 0.67 | -3.18 | 0.17 | 0.64 | 0.51 | 0.51 | 0.79 | 0.93 | 1.06 | 185 | 0.84 | 0.86 | 0.75 | 0.2 | 0.24 | 0.62 | 0.63 | 0.9 | 0.67 | 1.56 | 1.16 |
ROE % |
6.00 | 7.40 | 8.20 | 5.83 | 5.07 | 4.98 | 4.82 | 7.56 | 7.28 | 6.95 | 6.60 | 6.18 | 5.72 | 5.04 | 4.91 | 4.82 | 5.30 | 5.77 | 6.48 | 7.34 | 6.79 | 7.60 | 5.39 | 6.38 | 6.12 | 6.37 | 9.31 | 8.66 | 9.51 | 6.00 | 5.54 | 4.95 | 9.26 | 12.47 | 11.18 | 10.16 | 5.13 | 4.26 | 2.93 | 0.81 | -3.22 | -4.76 | -3.21 | -0.20 | 5.04 | 7.38 | 8.05 | 9.41 | 8.90 | 8.66 | 8.49 | 7.01 | 4.05 | 0.37 | -0.78 | -1.01 | 1.35 | 4.43 | 5.48 | 7.11 | 1.51 | 1.84 | 2.56 |
ROA % |
3.04 | 3.77 | 4.17 | 3.01 | 2.65 | 2.60 | 2.50 | 3.84 | 3.67 | 3.51 | 3.35 | 3.15 | 2.90 | 2.53 | 2.44 | 2.43 | 2.70 | 3.05 | 3.54 | 4.03 | 3.76 | 4.06 | 2.82 | 3.20 | 3.02 | 3.08 | 4.46 | 4.07 | 4.43 | 2.78 | 2.21 | 1.75 | 2.85 | 3.90 | 3.41 | 3.06 | 1.42 | 1.12 | 0.76 | 0.22 | -0.90 | -1.29 | -0.31 | 0.97 | 3.29 | 4.80 | 5.19 | 6.02 | 5.63 | 5.38 | 5.11 | 4.08 | 2.35 | 0.25 | -0.40 | -0.53 | 0.73 | 2.44 | 3.05 | 3.90 | 0.86 | 1.04 | 1.36 |
ROCE % |
4.71 | 5.60 | 6.41 | 7.01 | 7.25 | 7.45 | 7.44 | 7.16 | 6.76 | 6.64 | 6.34 | 6.30 | 5.80 | 5.10 | 4.82 | 4.45 | 4.54 | 4.89 | 5.41 | 6.07 | 6.13 | 6.36 | 4.95 | 5.36 | 5.15 | 5.56 | 7.43 | 7.22 | 8.02 | 7.78 | 7.24 | 6.60 | 5.90 | 5.35 | 4.99 | 4.85 | 4.31 | 4.34 | 4.06 | 3.47 | 2.50 | 1.26 | 1.68 | 2.35 | 4.79 | 6.58 | 7.42 | 9.07 | 8.62 | 8.84 | 8.65 | 7.73 | 6.30 | 4.42 | 3.66 | 3.21 | 4.62 | 6.10 | 7.18 | 9.64 | 1.75 | 2.46 | 3.84 |
Current Ratio |
2.0 | 2.0 | 2.0 | 2.0 | 2.1 | 2.0 | 1.9 | 2.1 | 2.0 | 2.0 | 2.0 | 2.1 | 2.1 | 2.0 | 2.0 | 2.0 | 2.0 | 2.0 | 2.1 | 2.1 | 2.3 | 2.3 | 2.2 | 2.1 | 2.0 | 1.9 | 1.9 | 2.0 | 1.9 | 1.9 | 1.8 | 1.8 | 1.8 | 1.5 | 1.5 | 1.5 | 1.4 | 1.4 | 1.4 | 1.3 | 1.4 | 1.3 | 1.3 | 1.4 | 2.9 | 3.0 | 3.0 | 2.8 | 2.8 | 2.8 | 2.8 | 2.5 | 2.5 | 2.3 | 2.2 | 2.2 | 2.2 | 2.2 | 2.2 | 2.1 | 2.3 | 2.3 | 2.1 |
DSO |
69.4 | 65.5 | 69.9 | 63.4 | 59.7 | 55.4 | 54.4 | 49.4 | 51.0 | 50.9 | 52.4 | 51.6 | 53.2 | 55.5 | 57.2 | 61.3 | 58.3 | 54.7 | 55.8 | 52.4 | 52.7 | 49.9 | 50.6 | 52.1 | 57.8 | 66.0 | 54.4 | 57.3 | 65.3 | 63.1 | 58.3 | 58.1 | 60.9 | 65.2 | 68.2 | 62.9 | 69.2 | 69.2 | 71.5 | 50.2 | 50.5 | 49.2 | 53.7 | 84.8 | 71.7 | 60.7 | 66.6 | 63.7 | 65.4 | 64.1 | 60.5 | - | 73.3 | 70.1 | 75.5 | 70.4 | 67.6 | 63.1 | 62.6 | 59.5 | 60.0 | 59.9 | - |
DIO |
74.3 | 74.4 | 74.4 | 68.0 | 70.8 | 69.2 | 73.0 | 70.3 | 77.9 | 78.6 | 74.9 | 71.3 | 72.1 | 70.4 | 70.2 | 78.7 | 72.2 | 65.2 | 65.4 | 60.2 | 60.6 | 61.6 | 67.2 | 71.4 | 84.4 | 85.8 | 66.5 | 66.8 | 83.6 | 77.4 | 74.9 | 81.6 | 83.2 | 91.9 | 90.9 | 92.7 | 111.8 | 111.1 | 81.9 | -5621.0 | 98.8 | 98.3 | 98.5 | 77.7 | 146.2 | 108.5 | 111.9 | 104.6 | 100.2 | 95.9 | 92.5 | 92.3 | 99.9 | 96.2 | 103.1 | 92.6 | 92.9 | 90.0 | 90.4 | 105.8 | 114.5 | 100.5 | - |
DPO |
29.2 | 29.5 | 31.5 | 29.4 | 30.5 | 30.1 | 30.7 | 29.9 | 34.2 | 34.6 | 35.7 | 35.0 | 33.8 | 35.9 | 38.0 | 39.8 | 36.4 | 34.3 | 33.2 | 28.7 | 28.1 | 26.9 | 25.2 | 24.9 | 28.0 | 33.3 | 28.4 | 26.0 | 32.7 | 30.5 | 26.1 | 26.9 | 30.9 | 37.9 | 36.9 | 34.8 | 43.9 | 44.2 | 30.3 | -1893.6 | 34.0 | 33.0 | 31.8 | 26.2 | 48.6 | 34.3 | 37.5 | 37.1 | 35.7 | 35.0 | 35.0 | 31.8 | 32.3 | 34.4 | 40.6 | 38.0 | 36.6 | 36.7 | 35.9 | 33.5 | 33.2 | 34.4 | - |
Operating Cycle |
143.7 | 139.9 | 144.4 | 131.4 | 130.5 | 124.5 | 127.4 | 119.7 | 128.9 | 129.6 | 127.3 | 123.0 | 125.3 | 126.0 | 127.4 | 140.1 | 130.5 | 120.0 | 121.2 | 112.6 | 113.3 | 111.5 | 117.7 | 123.5 | 142.2 | 151.8 | 120.9 | 124.0 | 148.9 | 140.5 | 133.2 | 139.6 | 144.1 | 157.1 | 159.1 | 155.5 | 181.0 | 180.3 | 153.5 | -5570.8 | 149.3 | 147.5 | 152.1 | 162.6 | 217.8 | 169.2 | 178.5 | 168.3 | 165.6 | 160.0 | 152.9 | 92.3 | 173.3 | 166.2 | 178.6 | 163.0 | 160.5 | 153.2 | 153.0 | 165.3 | 174.5 | 160.4 | - |
Cash Conversion Cycle |
114.4 | 110.4 | 112.8 | 102.0 | 100.1 | 94.4 | 96.7 | 89.8 | 94.7 | 94.9 | 91.6 | 87.9 | 91.6 | 90.0 | 89.4 | 100.2 | 94.1 | 85.7 | 88.1 | 84.0 | 85.2 | 84.6 | 92.5 | 98.6 | 114.2 | 118.5 | 92.5 | 98.0 | 116.2 | 109.9 | 107.1 | 112.8 | 113.2 | 119.2 | 122.2 | 120.8 | 137.1 | 136.1 | 123.2 | -3677.2 | 115.3 | 114.5 | 120.4 | 136.3 | 169.3 | 134.8 | 141.0 | 131.2 | 129.9 | 125.0 | 117.8 | 60.5 | 141.0 | 131.9 | 138.0 | 125.0 | 123.8 | 116.5 | 117.1 | 131.9 | 141.3 | 125.9 | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Multiples are an important financial analysis tool for the company Integer Holdings Corporation, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Medical devices industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Abbott Laboratories
ABT
|
$ 110.59 | 0.07 % | $ 193 B |  USA |
 |
EDAP TMS S.A.
EDAP
|
- | - | $ 162 M |  France |
 |
Align Technology
ALGN
|
$ 174.54 | 0.16 % | $ 12.7 B | USA |
 |
TELA Bio
TELA
|
$ 0.83 | -4.37 % | $ 39 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
$ 104.0 | -0.68 % | $ 60.8 B | USA |
 |
Avinger
AVGR
|
- | -20.74 % | $ 369 K | USA |
 |
CONMED Corporation
CNMD
|
$ 51.21 | -1.42 % | $ 1.59 B | USA |
 |
Medtronic PLC
MDT
|
$ 101.59 | -1.17 % | $ 130 B | USA |
 |
MiMedx Group
MDXG
|
$ 3.37 | 1.36 % | $ 498 M | USA |
 |
ThermoGenesis Holdings
THMO
|
- | -25.84 % | $ 171 K | USA |
 |
Talis Biomedical Corporation
TLIS
|
- | 3.55 % | $ 7.96 M | USA |
 |
Myomo
MYO
|
$ 1.32 | -5.71 % | $ 55.2 M | USA |
 |
Insulet Corporation
PODD
|
$ 148.03 | -1.19 % | $ 10.4 B | USA |
 |
Profound Medical Corp.
PROF
|
$ 7.66 | 4.36 % | $ 232 M |  Canada |
 |
Quanterix Corporation
QTRX
|
$ 3.3 | -2.51 % | $ 141 M | USA |
 |
Viveve Medical
VIVE
|
- | -15.35 % | $ 1.71 M | USA |
 |
Smith & Nephew plc
SNN
|
$ 30.96 | -0.29 % | $ 26.8 B |  Britain |
 |
Sensus Healthcare
SRTS
|
$ 3.42 | 7.39 % | $ 55.8 M | USA |
 |
Stryker Corporation
SYK
|
$ 324.18 | -0.48 % | $ 124 B | USA |
 |
Tactile Systems Technology
TCMD
|
$ 26.61 | 0.08 % | $ 609 M | USA |
 |
TransMedics Group
TMDX
|
$ 91.02 | -2.95 % | $ 3.09 B | USA |
 |
SmileDirectClub
SDC
|
- | -53.45 % | $ 9.71 M | USA |
 |
Viemed Healthcare
VMD
|
$ 9.04 | 1.01 % | $ 352 M | USA |
 |
Varex Imaging Corporation
VREX
|
$ 18.45 | 0.03 % | $ 764 M | USA |
 |
Acutus Medical
AFIB
|
- | -26.83 % | $ 2.62 M | USA |
 |
Vivos Therapeutics
VVOS
|
$ 0.09 | -8.14 % | $ 925 K | USA |
 |
BIOLASE
BIOL
|
- | -13.19 % | $ 166 K | USA |
 |
SeaSpine Holdings Corporation
SPNE
|
- | 0.28 % | $ 270 M | USA |
 |
Xtant Medical Holdings
XTNT
|
$ 0.28 | -0.68 % | $ 39.1 M | USA |
 |
Zimmer Biomet Holdings
ZBH
|
$ 107.39 | -0.87 % | $ 21.3 B | USA |
 |
Apollo Endosurgery
APEN
|
- | - | $ 475 M | USA |
 |
NuVasive
NUVA
|
- | - | $ 2.07 B | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
$ 0.37 | 59.63 % | $ 24 M |  Israel |
 |
Penumbra
PEN
|
$ 321.48 | -0.11 % | $ 12.5 B | USA |
 |
Conformis
CFMS
|
- | - | $ 16.4 M | USA |
 |
ViewRay
VRAY
|
- | 1.54 % | $ 468 M | USA |
 |
Medigus Ltd.
MDGS
|
- | 10.28 % | $ 55.5 M | Israel |
 |
Boston Scientific Corporation
BSX
|
$ 44.68 | 1.49 % | $ 66.1 B | USA |
 |
Cutera
CUTR
|
- | -10.19 % | $ 1.99 M | USA |
 |
Neovasc
NVCN
|
- | - | $ 111 M | Canada |
 |
Vapotherm
VAPO
|
- | 6.72 % | $ 34 M | USA |
 |
Nevro Corp.
NVRO
|
- | - | $ 217 M | USA |
 |
Venus Concept
VERO
|
- | - | $ 726 K | USA |
 |
Eargo
EAR
|
- | - | $ 10.2 M | USA |
 |
Sientra
SIEN
|
- | -16.59 % | $ 10.3 M | USA |
 |
Silk Road Medical, Inc
SILK
|
- | - | $ 1.07 B | USA |
 |
Surgalign Holdings
SRGA
|
- | -32.98 % | $ 1.68 M | USA |
 |
Cardiovascular Systems
CSII
|
- | 0.15 % | $ 844 M | USA |
 |
ShockWave Medical
SWAV
|
- | - | $ 12.3 B | USA |
 |
Inari Medical
NARI
|
- | - | $ 4.23 B | USA |